Bronchopulmonary Dysplasia Pipeline Review, 2025

The global Bronchopulmonary Dysplasia pipeline has been evolving and expanding with the rising need for clinical treatment for the increasing rate of chronic lung diseases in premature infants. Bronchopulmonary Dysplasia (BPD) is a lung condition. Premature infants, those who are born before 32 weeks of gestation are generally affected by this disease as well as individuals who are with low birth weight. The characteristics of BPD are abnormal lung development and inflammation due to prolonged mechanical ventilation or oxygen therapy given to the patients for support. In severe conditions, it is observed that infants may develop chronic lung disease and experience frequent respiratory infections.

Some of the common symptoms of this disorder are labored or rapid breathing (tachypnea), wheezing, and difficulty feeding. Based on some clinical criteria the BPD is confirmed, such as dependence on oxygen of an infant and radiographic proof of lung abnormalities including hyperinflation, fibrosis visible on chest X-rays or atelectasis. Therefore, there is a growing need for focusing on Bronchopulmonary Dysplasia therapies that can manage symptoms along with supporting lung development in affected infants. Various companies and research academics are working toward assessing challenges and looking for opportunities that may influence Bronchopulmonary Dysplasia research and development. It is seen that the professionals and researchers are emphasizing on novel support to improve and treat BPD therapies that are under development.

Bronchopulmonary Dysplasia Pipeline Insights 2025: Report Scope

Covering 10+ companies and 12+ pipeline drugs, Fortune Business Insights has released its report “Bronchopulmonary Dysplasia Pipeline Insights 2025”. It presents an entire pipeline insight regarding clinical research and non-clinical stages of drug manufacturing and develops new treatments of Bronchopulmonary Dysplasia. The drugs under development are based on commercial assessment and clinical assessment, mechanism of action of the drugs. This report also presents pipeline reviews, including various stages such as phase 1, phase 2, and phase 3 trials of drugs development and treatments. The report covers major regions of geography such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Reasons to Buy this Report

• Develop effective expansion strategies derived by comprehensive overview of the R&D activity and Bronchopulmonary Dysplasia pipeline products for tumor therapies.
• Identify emerging firms in the market on the basis of pipeline products.
• Identify development plans to counteract the emergence of new players in the market.
• Identify the focus of R&D activities of top participants for Bronchopulmonary Dysplasia treatments.
• Identify potential of collaborations,acquisitions, and mergers on basis of licensing activities related to the treatment
• Analyse the causes for inactive and discontinued products to propose changes in R&D attention, if required.

Know Answers to Your Questions

• What is the number of companies developing Bronchopulmonary Dysplasia drugs?
• What are the numbers of Bronchopulmonary Dysplasia drugs developed by each company?
• What are the emerging drugs in their Phase 2 trials and Phase 3 trials of development for the treatment of Bronchopulmonary Dysplasia?
• What types of mergers and acquisitions, collaborations (Industry-Industry, Industry-Academia), and licensing activities related to the Bronchopulmonary Dysplasia therapeutics?
•  What are the latest trends, types of drugs, and new technologies developed to overcome the limitation of existing therapies?
• What are the ongoing clinical studies for Bronchopulmonary Dysplasia and their status?
• What are the main designations that have been approved for the new drugs?

Report Methodology

• These pipeline reports are created by the evaluation of data, which is primarily collected from credible desk research sources. In addition, secondary data has also been collected, which is supplemented by conducting interviews with expert opinion leaders.
• The desk research sources consist of annual reports, white papers, websites, news articles, and press releases and investor presentations of companies. It also includes databases from global and regional clinical trials, industrial associations published reports, as well as articles/ reports published on databases from internal databases, NCBI, and ResearchGate.

Clinical Trial Insights

The rising emphasis on requirement for needed drugs and effective therapies for lung disease prevention and curing are impelling demand for the development of drug pipelines which is pushing R&D activities. There are numerous healthcare institutes, players connected with the medical sectors, and diverse research organizations are conducting clinical trials for developing new drugs for treatment of bronchopulmonary dysplasia disorder. Government bodies have increased emphasis on improving infrastructure for healthcare, supporting the worldwide clinical trials scenario in the field of bronchopulmonary dysplasia treatment.

Bronchopulmonary Dysplasia Pipeline Overview

Escalating awareness activities and encouraging government policies has encouraged development initiatives for products. Different new drug candidates are under preclinical as well as discovery stages and are in their Phase 1, Phase 2, and Phase 3 trials. There are other developments in the market including collaborations, merger, and licensing as well as thorough therapeutic assessment for emerging drugs. To bring candidates to the market, key healthcare companies are also keen to look for drug approvals from regulatory bodies.

A brief coverage of bronchopulmonary dysplasia emerging drugs in pipeline:

OHB-607: Oak Hill Bio

OHB-607, early called TAK-607, is a new therapeutic candidate that is produced by Oak Hill Bio and it is in Phase 2 trials stage. It is developed with an aim to address health challenges that extremely premature infants may face. This drug is a recombinant version of insulin-like growth factor 1 (IGF-1) and it is combined with binding protein IGFBP-3. It is dedicatedly made for preventing BPD. OHB-607 intended to restore IGF-1 level present in full-term pregnancies, therefore supporting normal growth and development of critical organs for instance brain, eyes, and lungs.

AT-100: Airway Therapeutics, Inc

AT-100 is an innovative biologic developed by Airway Therapeutics, Inc. It is also called Zelpultide Alfa. It is a collective edition of rhSP-D (human surfactant protein D). It is engineered to decrease inflammation and infection alongside the modulation of immune responses. This therapeutic candidate is in its Phase 1 trial stages of development and mainly targeting to bronchopulmonary dysplasia (BPD).